Drug Type Small molecule drug |
Synonyms Temuterkib Mesylate, LY 3214996, LY3214996 |
Target |
Mechanism ERK inhibitors(ERK subfamily inhibitors), ERK1 inhibitors(Extracellular-signal-regulated kinase1 inhibitors), ERK2 inhibitors(Extracellular-signal-regulated kinase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H27N7O2S |
InChIKeyJNPRPMBJODOFEC-UHFFFAOYSA-N |
CAS Registry1951483-29-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced cancer | Phase 2 | US | 27 May 2020 | |
Metastatic Pancreatic Cancer | Phase 2 | US | 27 May 2020 | |
Acute Myeloid Leukemia | Phase 1 | US | 15 Jul 2020 | |
Recurrent Glioblastoma | Phase 1 | US | 11 Jul 2020 | |
CD19 Expressing Malignancies | Phase 1 | - | 03 Feb 2020 | |
Chronic Lymphocytic Leukemia | Phase 1 | - | 03 Feb 2020 | |
Mantle-Cell Lymphoma | Phase 1 | - | 03 Feb 2020 | |
Marginal Zone B-Cell Lymphoma | Phase 1 | - | 03 Feb 2020 | |
Waldenstrom Macroglobulinemia | Phase 1 | - | 03 Feb 2020 | |
Colorectal Cancer | Phase 1 | US | 29 Sep 2016 |
Phase 2 | 52 | (LY3214996 and HCQ Combination) | ownmtxprmf(lltppudvce) = shykimfkkf htzurlzbrm (iwqfgbaoqj, krrxwpruax - ilcdtfyupi) View more | - | 27 Nov 2024 | ||
(LY3214996-Monotherapy) | ownmtxprmf(lltppudvce) = uhcveeaxez htzurlzbrm (iwqfgbaoqj, vwpfqbanty - zisrlvdnfi) View more | ||||||
Phase 2 | 16 | tcecmaaysl(rnqbxkqnup) = guixpnymsu eclnmmtbnu (plhfaotjix, sabpokljqb - bvogbxuqnx) View more | - | 07 Aug 2024 | |||
NCT04534283 (ASCO2023) Manual | Phase 2 | 12 | dzdrreuiyx(jhywnuyytm) = cypugjpinh flzcjkxmfx (uemcjuetro ) View more | Positive | 31 May 2023 | ||
Early Phase 1 | - | vwlaunxilx(zogzvkkiak) = uhdlizzfqv yuiediyitk (ylwgqnvudw ) | - | 12 Nov 2021 | |||
vwlaunxilx(zogzvkkiak) = wyushnfale yuiediyitk (ylwgqnvudw ) | |||||||
Phase 1 | 51 | rxlbpbtwzu(nhxixjrfhj) = grade (G) 3 cough and fatigue, G3 dehydration, increased creatinine (Cr), G3 increased CPK, G3 rash > 7 days, and 1 pt with renal failure. wgneradvdq (ecmudbbmqv ) View more | Positive | 03 Jun 2019 | |||
Phase 1 | - | 210 | hhwcakeref(rilmqgclgu) = dfszoaxiza aptwntgyls (qgkoyortvt ) | - | 01 Jul 2017 | ||
Phase 1 | 210 | mxgvlwworr(bvuvcrfyfy) = rvsgjgaawd phaoepkdij (uucbjsifbe ) | Positive | 01 Jul 2017 |